Alex Thompson
Stock Analyst at Stifel
(1.66)
# 3,089
Out of 4,786 analysts
33
Total ratings
50%
Success rate
-9.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| THRD Third Harmonic Bio | Downgrades: Hold | $23 → $5 | $3.47 | +44.09% | 2 | Mar 28, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $36 | $8.01 | +349.44% | 1 | Mar 25, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Buy | $60 | $33.54 | +78.89% | 1 | Mar 25, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $200 → $207 | $155.86 | +32.81% | 2 | Nov 15, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $49 | $10.26 | +377.58% | 1 | Oct 11, 2024 | |
| ARGX argenx SE | Maintains: Buy | $485 → $500 | $591.87 | -15.52% | 4 | Jun 24, 2024 | |
| SYRE Spyre Therapeutics | Reiterates: Buy | $36 → $54 | $16.14 | +234.68% | 2 | Mar 26, 2024 | |
| DNTH Dianthus Therapeutics | Initiates: Buy | $44 | $18.14 | +142.56% | 1 | Feb 15, 2024 | |
| VTYX Ventyx Biosciences | Maintains: Hold | $6 → $2 | $1.15 | +73.91% | 5 | Dec 18, 2023 | |
| TVTX Travere Therapeutics | Maintains: Hold | $8 → $10 | $17.92 | -44.20% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $39.07 | +76.61% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $1 | $1.53 | -34.64% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $13.48 | +196.74% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $1.22 | +3,178.69% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $17.09 | +98.95% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.35 | +2,344.44% | 1 | Dec 14, 2022 |
Third Harmonic Bio
Mar 28, 2025
Downgrades: Hold
Price Target: $23 → $5
Current: $3.47
Upside: +44.09%
Avalo Therapeutics
Mar 25, 2025
Initiates: Buy
Price Target: $36
Current: $8.01
Upside: +349.44%
Crinetics Pharmaceuticals
Mar 25, 2025
Initiates: Buy
Price Target: $60
Current: $33.54
Upside: +78.89%
Ascendis Pharma
Nov 15, 2024
Maintains: Buy
Price Target: $200 → $207
Current: $155.86
Upside: +32.81%
Oruka Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $49
Current: $10.26
Upside: +377.58%
argenx SE
Jun 24, 2024
Maintains: Buy
Price Target: $485 → $500
Current: $591.87
Upside: -15.52%
Spyre Therapeutics
Mar 26, 2024
Reiterates: Buy
Price Target: $36 → $54
Current: $16.14
Upside: +234.68%
Dianthus Therapeutics
Feb 15, 2024
Initiates: Buy
Price Target: $44
Current: $18.14
Upside: +142.56%
Ventyx Biosciences
Dec 18, 2023
Maintains: Hold
Price Target: $6 → $2
Current: $1.15
Upside: +73.91%
Travere Therapeutics
Dec 18, 2023
Maintains: Hold
Price Target: $8 → $10
Current: $17.92
Upside: -44.20%
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $39.07
Upside: +76.61%
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $1.53
Upside: -34.64%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $13.48
Upside: +196.74%
Aug 9, 2023
Initiates: Buy
Price Target: $40
Current: $1.22
Upside: +3,178.69%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $17.09
Upside: +98.95%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $1.35
Upside: +2,344.44%